Discontinuation of direct oral anticoagulants among patients with atrial fibrillation according to gender and cohabitation status: a nationwide cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Discontinuation of direct oral anticoagulants among patients with atrial fibrillation according to gender and cohabitation status : a nationwide cohort study. / Binding, Casper; Olesen, Jonas Bjerring; Lee, Christina Ji-Young; Lip, Gregory Y H; Sindet-Petersen, Caroline; Gislason, Gunnar; Bonde, Anders Nissen.

I: European Heart Journal - Cardiovascular Pharmacotherapy, Bind 8, Nr. 4, 2022, s. 353–362.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Binding, C, Olesen, JB, Lee, CJ-Y, Lip, GYH, Sindet-Petersen, C, Gislason, G & Bonde, AN 2022, 'Discontinuation of direct oral anticoagulants among patients with atrial fibrillation according to gender and cohabitation status: a nationwide cohort study', European Heart Journal - Cardiovascular Pharmacotherapy, bind 8, nr. 4, s. 353–362. https://doi.org/10.1093/ehjcvp/pvab065

APA

Binding, C., Olesen, J. B., Lee, C. J-Y., Lip, G. Y. H., Sindet-Petersen, C., Gislason, G., & Bonde, A. N. (2022). Discontinuation of direct oral anticoagulants among patients with atrial fibrillation according to gender and cohabitation status: a nationwide cohort study. European Heart Journal - Cardiovascular Pharmacotherapy, 8(4), 353–362. https://doi.org/10.1093/ehjcvp/pvab065

Vancouver

Binding C, Olesen JB, Lee CJ-Y, Lip GYH, Sindet-Petersen C, Gislason G o.a. Discontinuation of direct oral anticoagulants among patients with atrial fibrillation according to gender and cohabitation status: a nationwide cohort study. European Heart Journal - Cardiovascular Pharmacotherapy. 2022;8(4):353–362. https://doi.org/10.1093/ehjcvp/pvab065

Author

Binding, Casper ; Olesen, Jonas Bjerring ; Lee, Christina Ji-Young ; Lip, Gregory Y H ; Sindet-Petersen, Caroline ; Gislason, Gunnar ; Bonde, Anders Nissen. / Discontinuation of direct oral anticoagulants among patients with atrial fibrillation according to gender and cohabitation status : a nationwide cohort study. I: European Heart Journal - Cardiovascular Pharmacotherapy. 2022 ; Bind 8, Nr. 4. s. 353–362.

Bibtex

@article{8e1cfb6d1bc9425cacbee85fcc901331,
title = "Discontinuation of direct oral anticoagulants among patients with atrial fibrillation according to gender and cohabitation status: a nationwide cohort study",
abstract = "Aims The aim of this study was to evaluate the risk of discontinuing treatment with direct oral anticoagulants (DOACs) among patients with atrial fibrillation (AF) according to cohabitation status and gender. Methods and results Using the Danish national registers, we identified 32 364 patients with AF aged 40-90 years undergoing treatment with DOACs. The study period was from 2013 to 2017, and patients were followed for 2 years, or until death, outcome, or emigration. The main outcome was discontinuation of DOAC treatment for at least 30 days. The absolute 2-year risk of DOAC discontinuation was highest among men living alone [35.7%, 95% confidence interval (CI): 37.3-34.1%]. Men living alone had a 4.6% (95% CI: 6.4-2.8%) higher absolute risk of discontinuation and a 12% [hazard ratio (HR): 1.12, 95% CI: 1.04-1.20] higher relative risk of discontinuation compared with men living with a partner. Female patients living alone likewise had a higher absolute risk of DOAC discontinuation (2.6%, 95% CI: 4.4-0.09%) compared with female patients living with a partner, yet no statistically significant difference in relative risk. In an analysis evaluating gender, we found male gender to be associated with a significantly higher relative risk of DOAC discontinuation (HR: 1.33, 95% CI: 1.26-1.40) compared with female gender (P-value for interaction with cohabitant status = 0.5996). Conclusion In this nationwide population study, male gender and living alone were associated with a higher risk of DOAC discontinuation among patients with AF.",
keywords = "Atrial fibrillation, DOAC, Anticoagulation, Compliance, Discontinuation, WARFARIN, RISK, ADHERENCE, OUTCOMES",
author = "Casper Binding and Olesen, {Jonas Bjerring} and Lee, {Christina Ji-Young} and Lip, {Gregory Y H} and Caroline Sindet-Petersen and Gunnar Gislason and Bonde, {Anders Nissen}",
year = "2022",
doi = "10.1093/ehjcvp/pvab065",
language = "English",
volume = "8",
pages = "353–362",
journal = "European Heart Journal - Cardiovascular Pharmacotherapy",
issn = "2055-6837",
publisher = "Oxford University Press",
number = "4",

}

RIS

TY - JOUR

T1 - Discontinuation of direct oral anticoagulants among patients with atrial fibrillation according to gender and cohabitation status

T2 - a nationwide cohort study

AU - Binding, Casper

AU - Olesen, Jonas Bjerring

AU - Lee, Christina Ji-Young

AU - Lip, Gregory Y H

AU - Sindet-Petersen, Caroline

AU - Gislason, Gunnar

AU - Bonde, Anders Nissen

PY - 2022

Y1 - 2022

N2 - Aims The aim of this study was to evaluate the risk of discontinuing treatment with direct oral anticoagulants (DOACs) among patients with atrial fibrillation (AF) according to cohabitation status and gender. Methods and results Using the Danish national registers, we identified 32 364 patients with AF aged 40-90 years undergoing treatment with DOACs. The study period was from 2013 to 2017, and patients were followed for 2 years, or until death, outcome, or emigration. The main outcome was discontinuation of DOAC treatment for at least 30 days. The absolute 2-year risk of DOAC discontinuation was highest among men living alone [35.7%, 95% confidence interval (CI): 37.3-34.1%]. Men living alone had a 4.6% (95% CI: 6.4-2.8%) higher absolute risk of discontinuation and a 12% [hazard ratio (HR): 1.12, 95% CI: 1.04-1.20] higher relative risk of discontinuation compared with men living with a partner. Female patients living alone likewise had a higher absolute risk of DOAC discontinuation (2.6%, 95% CI: 4.4-0.09%) compared with female patients living with a partner, yet no statistically significant difference in relative risk. In an analysis evaluating gender, we found male gender to be associated with a significantly higher relative risk of DOAC discontinuation (HR: 1.33, 95% CI: 1.26-1.40) compared with female gender (P-value for interaction with cohabitant status = 0.5996). Conclusion In this nationwide population study, male gender and living alone were associated with a higher risk of DOAC discontinuation among patients with AF.

AB - Aims The aim of this study was to evaluate the risk of discontinuing treatment with direct oral anticoagulants (DOACs) among patients with atrial fibrillation (AF) according to cohabitation status and gender. Methods and results Using the Danish national registers, we identified 32 364 patients with AF aged 40-90 years undergoing treatment with DOACs. The study period was from 2013 to 2017, and patients were followed for 2 years, or until death, outcome, or emigration. The main outcome was discontinuation of DOAC treatment for at least 30 days. The absolute 2-year risk of DOAC discontinuation was highest among men living alone [35.7%, 95% confidence interval (CI): 37.3-34.1%]. Men living alone had a 4.6% (95% CI: 6.4-2.8%) higher absolute risk of discontinuation and a 12% [hazard ratio (HR): 1.12, 95% CI: 1.04-1.20] higher relative risk of discontinuation compared with men living with a partner. Female patients living alone likewise had a higher absolute risk of DOAC discontinuation (2.6%, 95% CI: 4.4-0.09%) compared with female patients living with a partner, yet no statistically significant difference in relative risk. In an analysis evaluating gender, we found male gender to be associated with a significantly higher relative risk of DOAC discontinuation (HR: 1.33, 95% CI: 1.26-1.40) compared with female gender (P-value for interaction with cohabitant status = 0.5996). Conclusion In this nationwide population study, male gender and living alone were associated with a higher risk of DOAC discontinuation among patients with AF.

KW - Atrial fibrillation

KW - DOAC

KW - Anticoagulation

KW - Compliance

KW - Discontinuation

KW - WARFARIN

KW - RISK

KW - ADHERENCE

KW - OUTCOMES

U2 - 10.1093/ehjcvp/pvab065

DO - 10.1093/ehjcvp/pvab065

M3 - Journal article

C2 - 34415024

VL - 8

SP - 353

EP - 362

JO - European Heart Journal - Cardiovascular Pharmacotherapy

JF - European Heart Journal - Cardiovascular Pharmacotherapy

SN - 2055-6837

IS - 4

ER -

ID: 302824919